PrEP Continuation, HIV and STI Testing Rates, and Delivery of Preventive Care in a Clinic-Based Cohort. AIDS Educ Prev 2018 Oct;30(5):393-405
Date
10/18/2018Pubmed ID
30332309Pubmed Central ID
PMC6535209DOI
10.1521/aeap.2018.30.5.393Scopus ID
2-s2.0-85055077564 (requires institutional sign-in at Scopus site) 24 CitationsAbstract
HIV pre-exposure prophylaxis (PrEP) has been demonstrated to be a safe and effective method of reducing HIV incidence. Questions remain regarding PrEP's efficacy and outcomes in real-world clinical settings. We conducted a retrospective review to assess PrEP outcomes in an academic clinic setting and focused on retention in care, reasons for discontinuation, and receipt of appropriate preventive care (immunizations, HIV testing, and STI testing). One hundred thirty-four patients were seen between 2010 and 2016 over 309 visits. One hundred sixteen patients (87%) started daily PrEP and of those, 88 (76%) attended at least one 6-month follow-up visit. Over 60% of PrEP patients completed all recommended STI screening after starting PrEP. Only 40% of patients had all appropriate immunizations at baseline; 78% had all appropriate immunizations at study completion. This study demonstrated high rates of both retention and of attaining recommended preventive care in a clinical setting outside of the rigors of clinical trials.
Author List
Hevey MA, Walsh JL, Petroll AEAuthors
Andrew Petroll MD Professor in the Medicine department at Medical College of WisconsinJennifer L. Walsh PhD Associate Professor in the Psychiatry and Behavioral Medicine department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AdolescentAdult
Ambulatory Care Facilities
Anti-HIV Agents
Cohort Studies
Delivery of Health Care
Female
HIV Infections
Humans
Incidence
Male
Middle Aged
Patient Compliance
Pre-Exposure Prophylaxis
Primary Prevention
Retrospective Studies
Sexually Transmitted Diseases
Treatment Outcome
Young Adult
